Vaxcyte, Inc. - COMMON STOCK (PCVX)

Historical Holders from Q2 2020 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
PCVX on Nasdaq
Shares outstanding
129,929,313
Price per share
$46.14
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
141,274,894
Holdings value
$5,088,535,411
% of all portfolios
0.01%
Share change
-6,311,713
Value change
-$216,626,334
Average buys %
+0%
Average sells %
-0%
Number of holders
280
Price from insider filings
$46.69
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Vaxcyte, Inc. - COMMON STOCK (PCVX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 10% +7.8% $414,340,651 +$32,457,883 13,132,826 +8.5% FMR LLC 29 Aug 2025
JANUS HENDERSON GROUP PLC 10% -12% $472,013,392 -$57,168,819 13,104,203 -11% JANUS HENDERSON GROUP PLC 30 Sep 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% $426,531,754 12,964,491 RA Capital Management, L.P. 31 Mar 2025
BlackRock, Inc. 7.6% $323,263,490 9,825,638 BlackRock, Inc. 31 Mar 2025
T. Rowe Price Investment Management, Inc. 6.4% $299,523,446 8,315,476 T. Rowe Price Investment Management, Inc. 30 Sep 2025
As of 30 Sep 2025, Vaxcyte, Inc. - COMMON STOCK (PCVX) has 280 institutional shareholders filing 13F forms. They hold 141,274,894 shares .

Top 25 institutional shareholders own 87% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
JANUS HENDERSON GROUP PLC 10% 13,104,203 -11% 0.22% $472,046,873
FMR LLC 9.6% 12,509,933 +3% 0.02% $450,607,771
VANGUARD GROUP INC 9.5% 12,320,453 +2.7% 0.01% $443,782,718
RA CAPITAL MANAGEMENT, L.P. 9.2% 11,965,991 0% 5.3% $431,014,996
BlackRock, Inc. 7.7% 9,955,978 -6.4% 0.01% $358,614,332
T. Rowe Price Investment Management, Inc. 6.4% 8,315,295 +39% 0.18% $299,517,000
WELLINGTON MANAGEMENT GROUP LLP 3.9% 5,032,771 +1.6% 0.03% $181,280,411
STATE STREET CORP 3.7% 4,785,889 -3.2% 0.01% $172,387,722
D. E. Shaw & Co., Inc. 3.3% 4,290,790 +39% 0.12% $154,554,256
Paradigm Biocapital Advisors LP 2.9% 3,784,755 +12% 4% $136,326,875
WESTFIELD CAPITAL MANAGEMENT CO LP 2.9% 3,732,715 +22% 0.56% $134,452,394
Kynam Capital Management, LP 2.4% 3,071,588 0% 8.2% $110,638,600
Deep Track Capital, LP 2.3% 3,000,000 +40% 3% $108,060,000
GEODE CAPITAL MANAGEMENT, LLC 2.2% 2,884,040 -4.2% 0.01% $103,898,128
PRICE T ROWE ASSOCIATES INC /MD/ 1.3% 1,688,483 -47% 0.01% $60,820,000
JPMORGAN CHASE & CO 1.2% 1,565,036 +31% 0% $56,372,597
Eversept Partners, LP 1.1% 1,421,983 +9.5% 3.9% $51,219,828
Pivotal bioVenture Partners Investment Advisor LLC 1.1% 1,372,425 +5.2% 29% $49,434,749
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1% 1,293,407 -8.8% 0.01% $46,588,520
MAVERICK CAPITAL LTD 0.99% 1,289,567 -1.6% 0.62% $46,450,203
JENNISON ASSOCIATES LLC 0.9% 1,170,899 -16% 0.02% $42,175,782
NORTHERN TRUST CORP 0.83% 1,073,346 -4.3% 0% $38,661,924
Pictet Asset Management Holding SA 0.79% 1,029,629 -12% 0.04% $37,087,237
GOLDMAN SACHS GROUP INC 0.75% 975,377 +4.4% 0.01% $35,133,079
ROYAL BANK OF CANADA 0.73% 949,049 +27% 0.01% $34,184,000

Institutional Holders of Vaxcyte, Inc. - COMMON STOCK (PCVX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 11,440 $527,842 -$55,644 $46.14 4
2025 Q3 141,274,894 $5,088,535,411 -$216,626,334 $36.02 280
2025 Q2 147,479,114 $4,794,596,759 -$48,097,035 $32.51 292
2025 Q1 133,025,604 $5,021,104,716 -$42,905,782 $37.76 302
2024 Q4 140,784,610 $11,525,526,197 +$183,138,339 $81.86 318
2024 Q3 136,507,040 $15,592,116,896 +$1,498,526,683 $114.27 325
2024 Q2 122,578,572 $9,264,040,265 +$268,135,107 $75.51 264
2024 Q1 119,065,967 $8,130,427,051 +$1,115,777,265 $68.31 249
2023 Q4 103,087,407 $6,473,142,685 +$69,029,370 $62.80 223
2023 Q3 101,381,209 $5,166,522,410 +$77,032,504 $50.98 202
2023 Q2 99,996,517 $4,993,540,992 +$865,860,362 $49.94 194
2023 Q1 84,121,058 $3,152,798,116 +$159,886,756 $37.48 186
2022 Q4 81,609,487 $3,913,093,743 +$1,140,362,544 $47.95 197
2022 Q3 56,496,728 $1,356,264,990 +$122,059,625 $24.00 121
2022 Q2 51,432,581 $1,119,137,255 +$31,274,087 $21.76 103
2022 Q1 49,852,918 $1,203,855,921 +$69,029,421 $24.15 86
2021 Q4 44,718,114 $1,063,493,543 +$32,023,661 $23.79 84
2021 Q3 43,198,231 $1,095,966,337 -$195,558 $25.37 77
2021 Q2 43,222,434 $972,744,067 -$14,050,462 $22.51 74
2021 Q1 44,022,105 $869,193,186 +$26,485,491 $19.75 73
2020 Q4 42,260,768 $1,118,933,017 +$58,331,379 $26.57 83
2020 Q3 37,761,937 $1,857,382,730 +$103,777,823 $49.38 60
2020 Q2 35,950,832 $1,126,753,000 +$1,126,753,000 $31.61 38